arrow
M

Manuel Valladares-Ayerbes

instituto de biomedicina de sevilla (ibis)
H指数:24
被引数:1,899

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

更正:高血压作为贝伐珠单抗含药一线疗法在转移性乳腺癌和结直肠癌中的预测因素(BRECOL [GEICAM/2011-04] 研究)。

2025-11-250
OAAI
Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial

FTD/TPI联合贝伐珠单抗在难治性转移性结直肠癌患者中的疗效预测因素:SUNLIGHT III期试验西班牙队列的亚组分析

2025-05-080
PRE
Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer
2025-04-210
OAAI
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNu-1 and Phase II VISNu-2 Randomized Trials
2023-06-012
PRE
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
2023-03-016
OAAI
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
2022-12-0110
OAAI
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
EJSO
IF2.9
2022-05-013
PRE
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
2021-12-224
OA
Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
2021-09-010
OAAI
Upfront primary tumour resection (UPTR) and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2021-09-010
OAAI
Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNU trials
2021-07-010
PREAI
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNU-2 study
2021-04-0110
OAAI